B9D2
B9 domain-containing protein 2
Also known as: B9D2_HUMAN, MGC4093, MKS10, MKSR-2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9BPU9
- Gene
- B9D2
- Ensembl
- ENSG00000123810
- Chromosome
- 19
- Canonical length
- 175 aa
- Protein class
- Disease related genes, Human disease related genes, Predicted intracellular proteins
- Subcellular location
- Nucleoli,Golgi apparatus,Vesicles,Centrosome,Basal body
OverviewNCBI Gene
This gene encodes a B9 domain protein, which are exclusively found in ciliated organisms. The gene is upregulated during mucociliary differentiation, and the encoded protein localizes to basal bodies and cilia. Disrupting expression of this gene results in ciliogenesis defects. [provided by RefSeq, Oct 2009]
Canonical amino-acid sequenceUniProt
175 residues, UniProt reviewed canonical sequence.
>Q9BPU9|B9D2
1 MAEVHVIGQI IGASGFSESS LFCKWGIHTG AAWKLLSGVR EGQTQVDTPQ IGDMAYWSHP
61 IDLHFATKGL QGWPRLHFQV WSQDSFGRCQ LAGYGFCHVP SSPGTHQLAC PTWRPLGSWR
121 EQLARAFVGG GPQLLHGDTI YSGADRYRLH TAAGGTVHLE IGLLLRNFDR YGVECLocalizationUniProt · AlphaFold · HPA
Whether an antibody against B9D2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.29
- Highest tissue expression
- 17 nTPM
Expression across tissuesHPA
Tissue
- choroid plexus: 17 nTPM
- fallopian tube: 9.9 nTPM
- kidney: 8.8 nTPM
- bone marrow: 8.3 nTPM
- testis: 8.3 nTPM
- adrenal gland: 8.2 nTPM
Single-cell type
- respiratory ciliated cells: 96 nCPM
- fallopian tube ciliated cells: 80 nCPM
- endometrial ciliated cells: 64 nCPM
- late spermatids: 56 nCPM
- epididymal efferent duct ciliated cells: 53 nCPM
- neutrophils: 37 nCPM
Immune cell
- neutrophil: 128 nTPM
- basophil: 47 nTPM
- classical monocyte: 32 nTPM
- plasmacytoid DC: 26 nTPM
- eosinophil: 26 nTPM
- T-reg: 25 nTPM
Brain region
- choroid plexus: 13 nTPM
- hypothalamus: 6.8 nTPM
- midbrain: 5 nTPM
- spinal cord: 4.4 nTPM
- thalamus: 4.4 nTPM
- hippocampal formation: 4.3 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about B9D2.
Disease | AllUniProt
Conditions B9D2 is implicated in, by any mechanism.
- Meckel syndrome 10 (MKS10) MIM:614175
- Joubert syndrome 34 (JBTS34) MIM:614175
Disease | GeneticClinVar
10 pathogenic / likely-pathogenic of 107 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Joubert syndrome and related disorders
- Joubert syndrome
- Meckel syndrome, type 10
- Joubert syndrome 34
- Meckel-Gruber syndrome
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.58
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.13
- DepMap mean gene effect
- -0.05
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of B9D2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads B9D2 as an antibody target. Whether an autoantibody or antibody against B9D2 could matter depends on whether native B9D2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
B9D2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label B9D2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...